FDA panel backs Pfizer's Xeljanz as bowel disease treatment

(Reuters) - Pfizer Inc's Xeljanz should be approved to treat patients with moderate to severe ulcerative colitis, a chronic bowel disease, a U.S. Food and Drug Administration (FDA) advisory committee concluded on Thursday.